NCT00085124: Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia |
|
|
| Completed | 3 | 500 | US | oblimersen sodium, augmerosen, G3139, G3139 bcl-2 antisense oligodeoxynucleotide, Genasense, cytarabine, ARA-C, arabinofuranosylcytosine, arabinosylcytosine, Cytosar-U, cytosine arabinoside, daunorubicin hydrochloride, Cerubidin, Cerubidine, daunomycin hydrochloride, daunorubicin, RP-13057, laboratory biomarker analysis | National Cancer Institute (NCI) | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia | 06/07 | | | |
